Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
NVIDIA
NVDA
4
Vale SA
VALE
5
KB Home
KBH
US Stock MarketDetailed Quotes
AXSM Axsome Therapeutics
- 131.150
- -0.530-0.40%
Close Feb 14 16:00 ET
- 131.090
- -0.060-0.05%
Post 20:01 ET
6.36BMarket Cap-19.93P/E (TTM)
132.120High129.350Low1.06MVolume131.610Open131.680Pre Close139.57MTurnover2.94%Turnover RatioLossP/E (Static)48.46MShares134.18552wk High68.41P/B4.75BFloat Cap64.11052wk Low--Dividend TTM36.23MShs Float134.185Historical High--Div YieldTTM2.10%Amplitude1.940Historical Low131.155Avg Price1Lot Size
About Axsome Therapeutics Company
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview contain AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Company Profile
SymbolAXSM
Company NameAxsome Therapeutics
Listing DateNov 19, 2015
Issue Price9.00
Founded2012
CEODr. Herriot Tabuteau, M.D.
MarketNASDAQ
Employees545
Fiscal Year Ends12-31
AddressOne World Trade Center,22nd floor
CityNew York
ProvinceNew York
CountryUnited States of America
Zip Code10007
Phone1-212-332-3241
Websitehttp://www.axsome.com
Company Executives
- Name
- Position
- Salary
- Dr. Herriot Tabuteau, M.D.
- Chairman of the Board, President and Chief Executive Officer
- 9.90M
- Mark Jacobson, M.A.
- Chief Operating Officer
- 4.04M
- Nick Pizzie
- Chief Financial Officer and Principal Accounting Officer
- 3.57M
- Lori Englebert
- Executive Vice President, Product Strategy
- --
- Ari Maizel
- Executive Vice President, Head of Commercial
- --
- Dr. Susan Mahony, M.B.A.,PhD
- Independent Director
- 417.48K
- Mark E. Saad
- Independent Director
- 405.34K
- Dr. Mark Coleman, M.D.
- Independent Director
- 427.84K
- Dr. Roger A. Jeffs, PhD
- Lead Independent Director
- 400.34K
- Hunter Murdock
- General Counsel
- 3.06M
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Unlock Now